Tweets
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/IagcDC24rZ
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
#RNL2023 - Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/Uh2RFrfpc2
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain &; odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/IcIQwP9z7C
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Study compared 491 SLE pts tested for ANCA Abs w/ 171 ANCA-associated vasculitis (AAV) pts. 46 SLE pts were ANCA+. ANCA-positive LN have worse baseline renal function and lower protein remission rates . https://t.co/fQCkBXJpO4
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
200 Biologic naive #RA pts in remission under csDMARD tapering and withdrawal while given either placebo or oral curcumin (1 g bid). Flare-free survival at 52 wks was similar between groups (60% vs 64%; p = 0.76). Time to flare was similar (219d vs 214d) https://t.co/m3j8HmjTT3 https://t.co/jDoAYN0eKQ
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
SGLT2 Inhibitors as Gout Treatment. Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said. https://t.co/zJVJuvCoIm https://t.co/kDLJynYczc
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
QD Clinic - Great Rheum Meetings
What makes for a great Rheumatology CME meeting?
https://t.co/tdb2crz8XP https://t.co/ZnMIhZpejO
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/szffvXtwaS
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
https://t.co/WZcJugj3Bg https://t.co/HQ3Xg9h0md
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Best of 2023: 25 Great Women in Rheumatology
https://t.co/9WgGbpILGb https://t.co/YN8QAHtyab
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
